Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
---|---|---|---|---|---|
PMID:2807101 | IVR | 0.5 % | 0.5 % | Changes in haemocrit values | Immunological endocrine-mediated perturbations |
IVR | 0.5 % | 0.5 % | Testicular carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
IVR | 0.2 % | 0.2 % | Testicular carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
IVR | 0.2 % | 0.2 % | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
PMID:3352650 | IVR | 120 mg/kg/day | 120 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations |
IVR | 120 mg/kg/day | 120 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
IVR | 60 mg/kg/day | 60 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
PMID:9207897 | IVR | 81 mg/L | - | No significant effects observed | - |
IVR | 2430 mg/L | 2430 mg/L | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
IVR | 2430 mg/L | 2430 mg/L | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.